How badly does Alexion want its Soliris follow-on? Enough to use a rare fast pass

Alexion Pharmaceuticals is trying to get a speedy approval of its Soliris follow-on drug, announcing Tuesday it used a valuable fast pass that shaves down the regulatory review time by several months.